Skip to content
Biotechnology

BioMed X Institute Starts Its First Research Project With Sanofi on Artificial Intelligence for Drug Development

The BioMed X Institute 3 mins read

Powered by Sanofi, a new BioMed X research team will develop a computational platform designed to accelerate drug development.

HEIDELBERG, GERMANY / ACCESSWIRE / June 29, 2023 / BioMed X, a German independent research institute, announces the start of its first research project in collaboration with Sanofi: "Next Generation Virtual Patient Engine for Clinical Translation of Drug Candidates" (VPE). The end goal of this research project is to develop a versatile computational platform that can predict the efficacy of first- or best-in-class drug candidates in virtual patient populations at unprecedented accuracy, thereby addressing one of the most critical bottlenecks of the pharmaceutical industry today: a 90% failure rate of new drug candidates during clinical development.

The BioMed X Institute, Thursday, June 29, 2023, Press release picture



The new research team will be led by Dr. Douglas McCloskey, a scientist and entrepreneur jointly selected by the Sanofi and BioMed X Institute management for the group leader position. "Most drug candidates that fail during clinical development do so due to a lack of efficacy compared to the standard of care. Our mission is to develop a platform to test-drive drug development candidates in virtual patients to gate the best ones into the clinic," explained the newly-appointed group leader of team VPE. "To tackle this challenge, our team at BioMed X will push the frontier of in silico drug discovery and development using our AI expertise with coaching from our industry partners," added Dr. McCloskey.

Christian Tidona, Founder and Managing Director of the BioMed X Institute: "After two years of collaborating on AI-powered drug discovery and development projects with our strategic partner in Israel, AION Labs, we are now ready to start our first AI-based research team in Heidelberg, Germany, together with our new pharma partner, Sanofi."

The "Next Generation Virtual Patient Engine for Clinical Translation of Drug Candidates" (VPE) team joins eight other active research teams at the BioMed X Institute in Germany, and it is one of four new projects launched by BioMed X in 2023. To learn more about this new AI-based research group, visit the BioMed X Institute website at www.bio.mx.

About BioMed X

BioMed X is an independent research institute located on the campus of the University of Heidelberg in Germany, with a worldwide network of partner locations. Together with our partners, we identify big biomedical research challenges and provide creative solutions by combining global crowdsourcing with local incubation of the world's brightest early-career research talents. Each of the highly diverse research teams at BioMed X has access to state-of-the-art research infrastructure and is continuously guided by experienced mentors from academia and industry. At BioMed X, we combine the best of two worlds - academia and industry - and enable breakthrough innovation by making biomedical research more efficient, more agile, and more fun.

Contact Information

Flavia-Bianca Cristian
Recruiting & Communications Manager
fbc@bio.mx
+49 6221 426 11 706

SOURCE: BioMed X Institute

.


View source version on accesswire.com:
https://www.accesswire.com/763921/BioMed-X-Institute-Starts-Its-First-Research-Project-With-Sanofi-on-Artificial-Intelligence-for-Drug-Development

More from this category

  • Biotechnology, Medical Health Aged Care
  • 24/05/2024
  • 10:53
Neuroscience Research Australia

NeuRA CEO elected as 2024 Fellow of the Australian Academy of Science

Scientia Professor Matthew Kiernan AM CEO at Neuroscience Research Australia has been elected as a 2024 Fellow of the Australian Academy of Science,joining the…

  • Contains:
  • Biotechnology, Science
  • 23/05/2024
  • 07:49
Brandon Capital

Up to $5 million In Funding Available for Dementia and Cognitive Decline Innovations Through CUREator+

23 May 2024 Melbourne: The CUREator+ Dementia and Cognitive Decline incubator program, a partnership between Brandon BioCatalyst, ANDHealth and Dementia Australia, has opened its first funding round. Companies pioneering innovative health technologies to enhance the lives of individuals affected by dementia and cognitive decline are set to receive up to $5 million per project in non-dilutive project funding, a substantial boost for their innovative solutions. Funded by the Federal Government’s $20 billion Medical Research Future Fund (MRFF), the program aims to support the development of novel approaches, spanning therapeutics, diagnostics, assistive and medical devices and digital health technologies, that will…

  • Biotechnology, Seniors Interest
  • 20/05/2024
  • 13:23
Centre for Eye Research Australia, Cerulea Clinical Trials

New centre to bring more international eye clinical trials to Victoria and boost access to sight-saving therapies

A new clinical trial centre launched today in Melbourne will bring more international trials to Victoria and give people living with vision loss and blindness early access to sight-saving therapies.To mark World Clinical Trials Day, Victorian Deputy Premier and Minister for Medical Research, the Hon Ben Carroll, launched Cerulea Clinical Trials - a new specialist ophthalmic clinical trial facility established by the Centre for Eye Research Australia (CERA).Cerulea Clinical Trials is supported by a $10million investment from Breakthrough Victoria and is expected to deliver clinical trials to more than 2500 Victorians a year over the next decade and create 50…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.